lenalidomide has been researched along with AL Amyloidosis in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Hata, H; Kawano, Y; Matsuoka, M; Takashio, S; Tsujita, K; Ueda, M | 1 |
| Blevins, F; Bradshaw, GA; Choiniere, J; Fraser, CS; Hata, AN; Kalocsay, M; Li, C; Miller, JW; Presser, A; Qin, X; Sanchorawala, V; Sarosiek, KA; Sarosiek, S; Spetz, JKE; Yu, S | 1 |
| Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gakiopoulou, H; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Kostopoulos, I; Manios, E; Migkou, M; Ntalianis, A; Ntanasis-Stathopoulos, I; Papadopoulou, E; Papanikolaou, A; Papanota, AM; Psimenou, E; Roussou, M; Stamatelopoulos, K; Terpos, E; Tselegkidi, MI; Tsitsilonis, O; Ziogas, DC | 1 |
| Cheesman, S; Cohen, OC; Fontana, M; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Martinez-Naharro, A; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Wechalekar, AD; Whelan, CJ; Yong, K | 1 |
| Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J | 1 |
| Basset, M; Benner, A; Carpinteiro, A; Dittrich, T; Goldschmidt, H; Hansen, T; Hegenbart, U; Huhn, S; Jauch, A; Kimmich, CR; Müller-Tidow, C; Schönland, SO; Terzer, T; Veelken, K | 1 |
| Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD | 1 |
| Basset, M; Benner, A; Dittrich, T; Goldschmidt, H; Hegenbart, U; Hose, D; Jauch, A; Kimmich, CR; Krzykalla, J; Müller-Tidow, C; Schönland, SO; Schreck, N; Seckinger, A; Veelken, K | 1 |
| Prince, HM | 1 |
| Becker, N; Beimler, J; Benner, A; Bochtler, T; Freiberger, A; Gawlik, M; Goldschmidt, H; Hegenbart, U; Ho, AD; Hose, D; Hund, E; Jauch, A; Kimmich, C; Kristen, AV; Schönland, SO; Zorn, M | 1 |
| Cook, M; Denman, J; Manavi, K | 1 |
| Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F | 1 |
| Avivi, I; Cohen, Y; Duek, A; Gatt, ME; Leiba, M; Shaulov, A | 1 |
| Baaj, ME; Doghmi, K; Eddou, H; Maaroufi, HE; Mikdame, M; Moudden, MK; Zinebi, A | 1 |
| Hillengass, J; Iqbal, SM; Krabak, M; McCarthy, P; Sarow, J; Stecklein, K | 1 |
| Bagratuni, T; Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gakiopoulou, H; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Marinaki, S; Migkou, M; Ntalianis, A; Ntanasis-Stathopoulos, I; Papadopoulou, E; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E; Ziogas, DC | 1 |
| Cao, XX; Feng, J; Jiang, XY; Li, J; Miao, HL; Qiu, Y; Shen, KN; Zhang, CL; Zhang, L; Zhou, DB | 1 |
| Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST | 1 |
| Cohen, A; Iakobishvili, Z; Itchaki, G; Kornowski, R; Magen, H; Muchtar, E; Raanani, P; Rosenfeld, R; Shochat, T | 1 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Suzuki, K | 1 |
| Gertz, MA; Hayman, SR; Sher, T | 1 |
3 review(s) available for lenalidomide and AL Amyloidosis
| Article | Year |
|---|---|
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.
Topics: Adult; Aged; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Intestinal Perforation; Lenalidomide; Male; Middle Aged; Thalidomide | 2018 |
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide | 2013 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
2 trial(s) available for lenalidomide and AL Amyloidosis
| Article | Year |
|---|---|
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Physicians; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2022 |
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Remission Induction; Survival Analysis; Thalidomide | 2017 |
18 other study(ies) available for lenalidomide and AL Amyloidosis
| Article | Year |
|---|---|
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
Topics: Amyloidosis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Multiple Myeloma | 2022 |
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.
Topics: Amyloid; Animals; Antineoplastic Agents; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Mice; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proteomics; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Chromosome Aberrations; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Treatment Outcome | 2019 |
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local | 2020 |
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine | 2021 |
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Duplication; Chromosomes, Human, Pair 1; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Progression-Free Survival; Recurrence; Retrospective Studies | 2021 |
A cautionary tale of the use of lenalidomide and dexamethasone for relapsed/refractory immunoglobulin light chain (AL) amyloidosis.
Topics: Dexamethasone; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Thalidomide | 2021 |
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HIV Seropositivity; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Paraproteinemias; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
[Treatment of systemic AL amyloidosis: about 25 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Hospitals, Military; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Middle Aged; Multiple Myeloma | 2019 |
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2018 |
Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Plasma Cells; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |